Regulatory/Compliance Filing
Shukra Pharmaceuticals Name and Symbol Change Approved
NSE approved the company’s name change to Shukra Medtech Limited and trading symbol change to SHUKRAMED, effective November 20, 2026.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
5
Neutral
5
Bullish
4
Bearish
5
Neutral
5
Bullish
36
Bearish
0
Neutral
0
Bullish
32
Investor Presentation
Q4 FY25
Pharmaceuticals & Biotechnology
Pharmaceuticals
3,726 Cr
Low Risk
84.08
39.18
1.19
29.87
85.07
26.30
Sales CAGR
Profit CAGR
ROE
ROCE
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Shukra Medtech Ltd (SHUKRAMED) is currently trading at 84.20 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Shukra Pharmaceuticals Limited, founded in 1993, specializes in manufacturing and trading pharmaceutical formulations and conducting laboratory testing. Their offerings include a wide range of antibiotics, antifungal, antiviral, sedatives, and more. The company operates four key manufacturing divisions: tablets, capsules, liquid, and small volume parental, situated in Gujarat. It collaborates with major pharmaceutical manufacturers like Cadila Healthcare, Intas Pharmaceuticals, and others, aiding in the development of diverse drugs and formulations. In 2013-14, Shukra Pharmaceuticals underwent a significant restructuring, including the amalgamation of Proper Dealcomm Private Limited and re-organization through a high court-approved scheme. The company provides a broad spectrum of dosage forms to prestigious pharmaceutical companies worldwide, enhancing its market presence and industry reputation.
Over the past 52 weeks, Shukra Medtech Ltd has traded between a low of ₹26.30 and a high of ₹85.07. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Shukra Medtech Ltd has a market capitalization of approximately 3,725.60. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Shukra Medtech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 84.08 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,725.60 Cr, Shukra Medtech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Shukra Medtech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Shukra Medtech Ltd is 84.08. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Shukra Medtech reported Rs 38.54 crore of operating profit before working-capital changes for the half year ended September 30, 2026. A net Rs 38.10 crore working-capital outflow, led by receivables, inventory and other assets, reduced net operating cash to Rs 43.31 lakh.
Shukra Medtech’s eight subsidiaries reported a combined loss after tax of Rs 5.37 crore for the half year ended September 30, 2026. Their total comprehensive income was also negative Rs 5.37 crore before consolidation adjustments.
Shukra Medtech reported consolidated net profit of Rs 12.71 crore for the quarter ended September 30, 2026. This was compared with Rs 2.38 crore in the September 2025 quarter and Rs 12.96 crore in the June 2026 quarter.
Shukra Medtech reported standalone net profit of ₹16.01 crore for the quarter ended September 30, 2026. This compares with ₹2.38 crore in the corresponding quarter of FY26.